Advertisement
Screener

Aura Biosciences, Inc. (AURA) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Aura Biosciences, Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Aura Biosciences, Inc. return tang equity for the quarter ending 2026-06-30 was -41.56%, a change of 16.50% year-over-year.
  • Aura Biosciences, Inc. return tang equity for the quarter ending 2026-03-31 was -104.80%, a change of -30.80% year-over-year.
  • Aura Biosciences, Inc. return tang equity for the quarter ending 2025-12-31 was -77.56%, a change of -20.37% year-over-year.
  • Aura Biosciences, Inc. return tang equity for the quarter ending 2025-09-30 was -67.96%, a change of -20.31% year-over-year.
  • Aura Biosciences, Inc. return tang equity for fiscal 2025 was -77.56%, a change of -20.37% from fiscal 2024.
  • Aura Biosciences, Inc. return tang equity for fiscal 2024 was -57.19%, a change of -23.36% from fiscal 2023.
  • Aura Biosciences, Inc. return tang equity for fiscal 2023 was -33.83%, a change of -3.79% from fiscal 2022.
  • Aura Biosciences, Inc. return tang equity for fiscal 2022 was -30.05%, a change of -6.90% from fiscal 2021.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-41.56%-$131.01M$315.27M
2026-03-31-104.80%-$112.39M$107.25M
2025-12-31-77.56%-$106.19M$136.91M
2025-09-30-67.96%-$106.47M$156.67M
2025-06-30-58.05%-$101.38M$174.63M
2025-03-31-74.00%-$94.7M$127.97M
2024-12-31-57.19%-$86.92M$151.97M
2024-09-30-47.64%-$83.22M$174.67M
2024-06-30-42.14%-$80.69M$191.45M
2024-03-31-37.67%-$78.65M$208.78M
2023-12-31-33.83%-$76.41M$225.85M
2023-09-30-46.69%-$70.84M$151.72M
2023-06-30-40.99%-$68.23M$166.44M
2023-03-31-35.17%-$63.39M$180.26M
2022-12-31-30.05%-$58.76M$195.58M
2022-09-30-46.79%-$53.84M$115.05M
2022-06-30-36.23%-$46.78M$129.09M
2022-03-31-29.88%-$42.16M$141.09M
2021-12-31-23.14%-$35.25M$152.32M
2021-09-3021.77%-$28.52M-$131.02M
2021-06-3019.00%-$23.32M-$122.75M
2021-03-3118.06%-$20.62M-$114.19M
2020-12-3120.43%-$22.21M-$108.71M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-77.56%-$106.19M$136.91M
2024-12-31-57.19%-$86.92M$151.97M
2023-12-31-33.83%-$76.41M$225.85M
2022-12-31-30.05%-$58.76M$195.58M
2021-12-31-23.14%-$35.25M$152.32M
2020-12-3120.43%-$22.21M-$108.71M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Allogene Therapeutics, Inc. (ALLO)United States$0.574B-4.33
Prime Medicine, Inc. (PRME)United States$0.557B-3.54
4D Molecular Therapeutics, Inc. (FDMT)United States$0.733B-4.10
Autolus Therapeutics plc (AUTL)$0.506B-1.52
Entera Bio Ltd. (ENTX)$0.485B
REGENXBIO Inc. (RGNX)United States$0.477B-3.30
Solid Biosciences Inc. (SLDB)United States$0.802B-5.07
Tectonic Therapeutic, Inc. (TECX)United States$0.469B-7.68
Attovia Therapeutics, Inc. (ATTO)United States$0.828B
Eikon Therapeutics, Inc. (EIKN)United States$0.446B